Tests SKB264 with pembrolizumab in several solid tumor types
Tests SKB264 with pembrolizumab in adults with selected solid tumors.
Plain-language title generated from the registry record
Registry title: A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
Key facts
- Where
- Bordeaux, Caen Cedex 5, Clermont-Ferrand, Dijon, Marseille, Paris, Pierre-Bénite, and Poitiers, FranceSee the 8 sites
- Phase
- Phase 2
Where in France
- Institut BergonieBordeaux, FranceNo longer taking part
- Centre Francois BaclesseCaen Cedex 5, FranceNo longer taking part
- Centre Jean PerrinClermont-Ferrand, FranceNo longer taking part
- Centr Georges Francois LeclercDijon, FranceNo longer taking part
- Institut Paoli-CalmettesMarseille, FranceNo longer taking part
- Assistance Publique Hopitaux de ParisParis, FranceNo longer taking part
- Centre Hospitalier Lyon-SudPierre-Bénite, FranceNo longer taking part
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
- Trial code
- NCT05642780EU 2022-502654-14-00
- Record updated
- 19 May 2026
- Original description
The main purpose of this study is to see if SKB264 in combination with pembrolizumab is safe and effective in treating selected solid tumors.Read full original descriptionShow less
A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors
The main purpose of this study is to see if SKB264 in combination with pembrolizumab is safe and effective in treating selected solid tumors.
Inclusion: Male and/or females of age 18 years and older who have histologically or cytologically confirmed locally advanced or metastatic cancer or recurrent cancer (Cervical, Urothelial, Ovarian, Prostate or Endometrial cancer).
Exclusion: Subjects who received any chemotherapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks before the first dose of the study drug; Subjects with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or active Tuberculosis; Subjects with a history of allogeneic tissue or solid organ transplant; Subjects with active central nervous system tumors or metastases.